Pediatricians prefer Merck, GSK and Sanofi, says SDI study

Share this article:
Sanofi-Aventis jumped from sixth place to third in terms of its reputation among pediatricians, trailing only Merck and GlaxoSmithKline in the top spots, according to an SDI study.

When asked how Sanofi had garnered their favor this year, nearly 40% of the physicians surveyed credited the company's vaccines or immunization support programs. Sanofi ramped up detailing efforts by 45% this year, particularly in support of its Pentacel vaccine, an immunization for diphtheria, tetanus and other diseases, and Xyzal, the company's near-blockbuster allergy treatment.

In the US, Sanofi's sponsored meetings and events for pediatricians increased by almost 72% since last year, with almost half of the events promoting Pentacel or Xyzal.

“It's noteworthy that pediatricians' opinions of Sanofi-Aventis US were elevated so much in the course of one year, said Healther Alba, SDI senior product manager, in a statement.

SDI's pharma company image study surveyed close to 10,000 participants, including physicians nurse practitioners, physician assistants and others.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.